Dr. Wright most recently worked for Schering-Plough Corporation as Executive Director and Senior Project Leader of the Antiviral/Antifungal groups where he provided strategic leadership to the development project teams involved in drug development and commercialization. Prior to Schering-Plough, Dr. Wright was Vice-President of CNS/Pain Development, Project Management and Pharmacokinetics at Biovail Technologies where he led the clinical and pharmacokinetic teams to prepare a New Drug Application for Tramadol ER. Prior to Biovail, Dr. Wright had a long career at Pharmacia where he held several leadership roles, the most recent position as Senior Director, Project Leader for all CNS development projects. Dr. Wright obtained a Doctor of Pharmacy from the University of the Pacific in Stockton, CA, an M.B.A. from National University in San Diego and a Ph.D. in Pharmaceutical Sciences from the University of Kentucky.
About Neuromed
Neuromed is a privately held biopharmaceutical company developing new and improved pain medicines. We have three programs aimed at addressing this important unmet medical need. Neuromed acquired the U.S. marketing rights to OROS(R) Hydromorphone, an extended release formulation of hydromorphone in Phase 3 clinical development. In collaboration with Merck, Neuromed is researching compounds designed to block the N-type calcium channel, a target linked to pain signal transmission. Separately, Neuromed is also developing T-type calcium channel blockers aimed at treating acute and chronic pain as well as hypertension and epilepsy. For more information visit http://www.neuromed.com
---------------------------------------------
OROS(R) is a trademark of ALZA Corporation.
Neuromed cautions you that statements included in this press release
that are not a description of historical facts may be forward-looking
statements. Forward-looking sta
'/>"/>
| SOURCE Neuromed Pharmaceuticals Ltd. Copyright©2007 PR Newswire. All rights reserved |